Compared with rivaroxaban, abelacimab is associated with fewer bleeding events in patients with AF and moderate to high risk for stroke.

Use of DOACs in patients with ICH and AF resulted in a remarkable reduction in ischemic stroke, but that benefit was partially offset by an increase in ICH recurrence.

Novartis has announced its acquisition of Anthos Therapeutics, a Boston-based biopharmaceutical company focused on developing abelacimab, an inve ...

Novartis has announced its acquisition of Anthos Therapeutics, a Boston-based biopharmaceutical company focused on developing abelacimab, an investigational monoclonal antibody currently in Phase 3 ...

Novartis is buying Anthos Therapeutics from Blackstone’s drug development division, as it makes a bet on an experimental drug aimed at preventing strokes in patients with an irregular heart rhythm.

A rapid heartbeat and shortness of breath could be signs of atrial fibrillation (AFib), an irregular heartbeat. Dr. Jim Stone, a cardiac electrophysiologist at North Medical Center in Tupelo, helps ...

Novartis is buying Anthos Therapeutics from Blackstone’s drug development division, as it makes a bet on an experimental drug aimed at preventing strokes in patients with an irregular heart rhythm.

Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late-stage anticoagulant, to its ...

Novartis has agreed to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical ...

Novartis today announced that it has entered into an agreement to acquire privately-held Anthos Therapeutics, which the Swiss ...

Results from the AZALEA-TIMI 71 phase 2 trial showed great promise for abelacimab to transform care for high-risk patients with atrial fibrillation.

Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.